Back to Search Start Over

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies.

Authors :
Mazzoni, Alessio
Vanni, Anna
Spinicci, Michele
Lamacchia, Giulia
Kiros, Seble Tekle
Rocca, Arianna
Capone, Manuela
Di Lauria, Nicoletta
Salvati, Lorenzo
Carnasciali, Alberto
Mantengoli, Elisabetta
Farahvachi, Parham
Zammarchi, Lorenzo
Lagi, Filippo
Colao, Maria Grazia
Liotta, Francesco
Cosmi, Lorenzo
Maggi, Laura
Bartoloni, Alessandro
Rossolini, Gian Maria
Source :
Journal of Clinical Investigation. 3/15/2022, Vol. 132 Issue 6, p1-12. 12p.
Publication Year :
2022

Abstract

BACKGROUNDImmunization against SARS-CoV-2, the causative agent of COVID-19, occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last.METHODSWe performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to 1 year after infection and following mRNA vaccination in naive individuals and individuals recovered from COVID-19 infection.RESULTSWe found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly, especially in naive individuals. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naive individuals, whereas it was ineffective in previously SARS-CoV-2-infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to 1 year following natural infection in a cohort of unvaccinated individuals.CONCLUSIONShort-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. In naive individuals, a booster dose restored optimal anti-spike immunity, whereas the needs for vaccinated individuals who have recovered from COVID-19 have yet to be defined.FUNDINGThis study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), the University of Florence (project RICTD2122), the Italian Ministry of Health (COVID-2020-12371849), and the region of Tuscany (TagSARS CoV 2). [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00219738
Volume :
132
Issue :
6
Database :
Academic Search Index
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
155794054
Full Text :
https://doi.org/10.1172/JCI157990